Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effect of long-term treatment by Genotonorm on linear growth

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Hormones

Criteria

Inclusion Criteria:

• All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014

• All patients who have stopped during one year will be included if a signed written informed consent

Exclusion Criteria:

• Endocrine disease, except well substituted hypothyroidism

• Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)